Neos Therapeutics Inc (NASDAQ:NEOS) reached a new 52-week low during mid-day trading on Tuesday after JMP Securities lowered their price target on the stock from $22.00 to $10.00. JMP Securities currently has a market outperform rating on the stock. Neos Therapeutics traded as low as $2.27 and last traded at $2.27, with a volume of 29439 shares trading hands. The stock had previously closed at $2.45.

NEOS has been the subject of several other research reports. Zacks Investment Research lowered Neos Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 25th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 price target on shares of Neos Therapeutics in a research note on Wednesday, August 8th. Wells Fargo & Co dropped their price target on Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, August 9th. Finally, ValuEngine raised Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 18th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $13.67.

In other news, Director Alan L. Heller purchased 43,478 shares of the company’s stock in a transaction on Thursday, November 8th. The stock was purchased at an average price of $2.30 per share, with a total value of $99,999.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.40% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its holdings in shares of Neos Therapeutics by 8.4% in the third quarter. Franklin Resources Inc. now owns 2,493,239 shares of the company’s stock worth $12,092,000 after buying an additional 193,500 shares during the period. BlackRock Inc. increased its holdings in shares of Neos Therapeutics by 1.5% in the third quarter. BlackRock Inc. now owns 2,122,751 shares of the company’s stock worth $10,295,000 after buying an additional 31,469 shares during the period. Nexthera Capital LP purchased a new position in shares of Neos Therapeutics in the second quarter worth about $2,369,000. Proxima Capital Management LLC increased its holdings in shares of Neos Therapeutics by 34.1% in the second quarter. Proxima Capital Management LLC now owns 295,000 shares of the company’s stock worth $1,844,000 after buying an additional 75,000 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Neos Therapeutics by 10.7% in the second quarter. Northern Trust Corp now owns 294,678 shares of the company’s stock worth $1,842,000 after buying an additional 28,378 shares during the period. Hedge funds and other institutional investors own 45.99% of the company’s stock.

The firm has a market capitalization of $76.86 million, a P/E ratio of -0.84 and a beta of 0.44.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Friday, November 9th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.03). The company had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $14.80 million. Neos Therapeutics had a negative return on equity of 586.25% and a negative net margin of 133.46%. On average, equities research analysts expect that Neos Therapeutics Inc will post -1.8 earnings per share for the current year.

WARNING: “Neos Therapeutics (NEOS) Sets New 52-Week Low After Analyst Downgrade” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/11/14/neos-therapeutics-neos-sets-new-52-week-low-after-analyst-downgrade.html.

Neos Therapeutics Company Profile (NASDAQ:NEOS)

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Featured Article: Understanding Price to Earnings Ratio (PE)

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.